<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363383">
  <stage>Registered</stage>
  <submitdate>13/12/2012</submitdate>
  <approvaldate>17/12/2012</approvaldate>
  <actrnumber>ACTRN12612001305819</actrnumber>
  <trial_identification>
    <studytitle>Low Calorie Diet, Pre-biotics and Antibiotics for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)</studytitle>
    <scientifictitle>Very low calorie diet (VLCD) followed by antibiotic, and prebiotic supplementation is superior to VLCD alone in achieving sustained weight loss and resolution of Non-Alcoholic Fatty Liver Disease. </scientifictitle>
    <utrn>U1111-1137-6649</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non Alcoholic Fatty Liver Disease</healthcondition>
    <healthcondition>Obesity</healthcondition>
    <healthcondition>metabolic syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All patients recieve 4 weeks Optifast low calorie diet. Optifast will be a meal replacement three times a day. 2 cups of vegetables also allowed during the day (800cal/day). Patients then randomised to one of three arms. Arm 1 Placebo (1 week placebo antibiotic orally 3 times a day) and placebo prebiotic orally 3 times a day for 12 weeks), Arm 2 Placebo antibiotic (1 week placebo antibiotic orally 3 times a day) + Prebiotic (inulin) 8g orally pre-meals for 12 weeks. Arm 3 Antibiotic (metronidazole 3 times orally per day for 1 week) + Prebiotic (inulin), 8g pre-meals orally for 12 weeks</interventions>
    <comparator>ARM 1 is the placebo controlled arm
Placebo antibiotic: lactose in gelatine capsule, identicle to the metronidazole capsule 500mg tds. Duration of antibiotic placebo 1 week. 
Placebo pre-biotic: maltodextran powder 3x daily. Identicle container to the pre-biotic. No significant difference in taste and appearance to the inulin. Duration of placebo pre-biotic 12 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary outcome is maintenance of weight loss (Target 7% total body weight reduction)</outcome>
      <timepoint>4- weekly assessments up to end of treatment at 16 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Improved insulin sensitivity (diabetic control, HOMA-IR), through blood tests</outcome>
      <timepoint>4- weekly assessments up to end of treatment at 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Reduced Alanine transaminase (ALT) with blood testing</outcome>
      <timepoint>4- weekly assessments up to end of treatment at 16 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Reduced hepatic steatosis with a fibroscan CAP (similar to an ultrasound of the liver)</outcome>
      <timepoint>Performed at baseline and at end of treatment at 16 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Non alcoholic fatty liver disease</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Alcohol &gt;20g/d
Medications which cause steatohepatitis
Severe medical conditions
Allergy to metronidazole
Inflammatory bowel disease
Pregnany
Decompensated liver disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>False</masking1>
    <masking2>False</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>31/01/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Auckland District Health Board, Medical research unit</primarysponsorname>
    <primarysponsoraddress>Level 14, Support Bldg, 
Auckland City Hospital.
Private Bag 92024, 
Auckland
1148</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Auckland Medical Research fund</fundingname>
      <fundingaddress>Level 14, Support Bldg, Auckland City Hospital.
Private Bag 92024, Auckland
1148</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to initiate weight loss with a very low calorie diet for 4-weeks, then alter gastrointestinal flora using prophylactic antibiotic therapy followed by prebiotic supplementation (with the usual diet) and assess efficacy in maintaining weight loss and amelioration of non alcoholic fatty liver disease.  This will be a randomised controlled trial. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern X Regional Ethics Commitee</ethicname>
      <ethicaddress>Private Bag 92522
Wellesley Street
Auckland
1141</ethicaddress>
      <ethicapprovaldate>3/10/2012</ethicapprovaldate>
      <hrec>NTX/12/05/040</hrec>
      <ethicsubmitdate>21/05/2012</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>David Orr</name>
      <address>NZLTU, Level 15 Support Building
Auckland Hospital
Grafton, PO box 92024
1148</address>
      <phone>006493074949</phone>
      <fax />
      <email>dorr@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>David Orr</name>
      <address>NZLTU, Level 15 Support Building
Auckland Hospital
Grafton, PO box 92024
1148</address>
      <phone>006493074949</phone>
      <fax />
      <email>dorr@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>David Orr</name>
      <address>NZLTU, Level 15 Support Building
Auckland Hospital
Grafton, PO box 92024
1148</address>
      <phone>006493074949</phone>
      <fax />
      <email>dorr@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>